Filgrastim biosimilar - Ratiopharm/Teva
Alternative Names: Biograstim (Teva); Filgrastim BS Inj.; Filgrastim NK; Granix; Leucocyte growth factor - Teva; Leukocyte growth factor - Teva; Neutroval™; Ratiograstim; Short-acting G-CSF - Teva; Short-acting Granulocyte Colony Stimulating Factor - Teva; tbo-filgrastim; Tevagrastim; XM-02; XM02-filgrastimLatest Information Update: 12 Nov 2021
At a glance
- Originator Ratiopharm; SICOR Biotech UAB
- Developer Nippon Kayaku; Ratiopharm; SICOR Biotech UAB; Teva Pharmaceutical Industries; Teva Pharmaceuticals Europe; Teva-KOWA-Pharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 06 Aug 2018 Registered for Neutropenia (In adolescents, In children, In infants) in USA (SC)
- 06 Aug 2018 Teva Pharmaceutical Industries plans to launch Granix® vials for Neutropenia (In adolescents, In children, In infants) in USA
- 09 Dec 2017 Adverse events and immunogenecity data from a phase II trial in Neutropenia (In pediatrics) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)